Redlands Daily Facts

Biotech Fund Dumps $12.3 Million in Crinetics Stock as Shares Remain 19% Lower on the Year ↗

November 27, 2025

Here’s what a complete fund exit reveals about sentiment toward one of biotech’s endocrine drug developers.

Crinetics Announces First Patient Randomized in Pivotal Phase 3 CAREFNDR Trial Evaluating Paltusotine in Carcinoid Syndrome

Topics Regulatory Compliance

November 20, 2025

Retail Chatter Surges As Crinetics Wins FDA Nod For First Oral Acromegaly Drug — Traders Expect Big Price Move ↗

Earnings Scheduled For November 6, 2025 ↗

November 06, 2025

Via Benzinga

September 25, 2025

Via Stocktwits

Crinetics Pharmaceuticals Announces November 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 10, 2025

The company is preparing a rollout of its recently FDA-approved acromegaly treatment.

Why Crinetics Pharmaceuticals Stock Was Sliding on Friday ↗

November 07, 2025

Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) Emerges as a Technical Breakout Candidate ↗

November 07, 2025

Crinetics Pharmaceuticals (CRNX) shows strong technical momentum and a high-quality consolidation setup, signaling a potential breakout opportunity for traders.

Via Chartmill

Crinetics Pharmaceuticals (NASDAQ:CRNX) Reports Q3 2025 Earnings Miss ↗

November 06, 2025

Crinetics Q3 2025 earnings miss estimates as it transitions to a commercial-stage company following the U.S. launch of its new drug, PALSONIFY.

Via Chartmill

Topics Earnings

Crinetics Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

November 06, 2025

Crinetics to Highlight Neuroendocrine Tumor Research Progress at the 2025 North American Neuroendocrine Tumor Society Annual Meeting

October 23, 2025

Preliminary analysis of one-year progression-free survival data from Phase 2 study of novel SST2 agonist paltusotine under investigation for carcinoid syndrome demonstrated potential anti-tumor...

Fastenal Posts Downbeat Earnings, Joins Vince Holding And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗

October 13, 2025

Via Benzinga

Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 10, 2025

Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025

October 06, 2025

The FDA just handed this clinical-stage biotech its golden ticket -- but at a $4.3 billion valuation, the market's already pricing in a fair amount of commercial success.

Is Crinetics Pharmaceuticals Stock a Buy? ↗

September 28, 2025

Gainers Indaptus Therapeutics (NASDAQ: INDP) stock moved upwards by 108.1% to $6.83 during Friday's regular session. The market value of their outstanding shares is at $3.6 million.

FDA Approves Crinetics Pharma's First Daily Pill For Rare Growth Disorder ↗

September 26, 2025

On Thursday, the U.S.

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

September 26, 2025

Via Benzinga

Friday's session: gap up and gap down stocks ↗

September 26, 2025

Let's have a look at the gap up and gap down stocks in today's session.

Via Chartmill

Crinetics Pharmaceuticals, BlackBerry, Perpetua Resources And Other Big Stocks Moving Higher On Friday ↗

September 26, 2025

U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Friday. Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) rose sharply during Friday's session after the FDA...

Via Benzinga

Topics Stocks

Assessing Crinetics Pharmaceuticals: Insights From 4 Financial Analysts ↗

September 26, 2025

Throughout the last three months, 4 analysts have evaluated Crinetics Pharmaceuticals (NASDAQ: CRNX), offering a diverse set of opinions from bullish to bearish. Summarizing their recent assessments,...

Via Benzinga

Crinetics Pharma Surges After FDA OKs Its Treatment For A Form Of Gigantism ↗

September 26, 2025

The company's drug, Palsonify, treats acromegaly, a condition in which the pituitary gland makes too much growth hormone.

Via Investor's Business Daily

Topics Artificial Intelligence

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

September 26, 2025

Gainers bioAffinity Technologies (NASDAQ: BIAF) stock increased by 71.8% to $5.86 during Friday's pre-market session. The company's market cap stands at $4.5 million.

Via Benzinga

Crinetics Announces FDA Approval of PALSONIFY™ (paltusotine) for the Treatment of Adults with Acromegaly

September 25, 2025

Crinetics Pharmaceuticals Announces September 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 10, 2025

Crinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH)

August 21, 2025

Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers.

Tuesday's pre-market session: top gainers and losers ↗

August 19, 2025

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

August 19, 2025

Via Benzinga

Crinetics Pharmaceuticals Announces August 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 11, 2025

Crinetics (CRNX) Q2 Revenue Jumps 150% ↗

August 07, 2025

Crinetics Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Topics Intellectual Property

August 07, 2025